L3VLUP
ProSign in

RPRX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RPRXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RPRX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterRPRXVRTX
Q3 20207 holders, $1.6bn31 holders, $21.9bn
Q4 20205 holders, $1.9bn30 holders, $18.4bn
Q1 20215 holders, $1.5bn31 holders, $15.4bn
Q2 20218 holders, $1.5bn30 holders, $12.7bn
Q3 20216 holders, $1.4bn35 holders, $10.1bn
Q4 20218 holders, $1.8bn28 holders, $12.4bn
Q1 20228 holders, $1.8bn23 holders, $16.1bn
Q2 202210 holders, $3.2bn25 holders, $18.1bn
Q3 202211 holders, $3.4bn22 holders, $18.4bn
Q4 202217 holders, $3.4bn28 holders, $18.4bn
Q1 202314 holders, $2.9bn26 holders, $21.4bn
Q2 202316 holders, $2.3bn27 holders, $24.7bn
Q3 202314 holders, $1.9bn33 holders, $24.3bn
Q4 202313 holders, $2.1bn32 holders, $28.6bn
Q1 202410 holders, $2.2bn31 holders, $29.8bn
Q2 202412 holders, $1.7bn29 holders, $33.4bn
Q3 202410 holders, $2.0bn27 holders, $33.5bn
Q4 202410 holders, $1.6bn26 holders, $28.5bn
Q1 20259 holders, $2.3bn21 holders, $35.4bn
Q2 20259 holders, $2.4bn21 holders, $32.3bn
Q3 202511 holders, $1.9bn22 holders, $25.9bn
Q4 202510 holders, $2.4bn26 holders, $31.8bn
Q1 202615 holders, $3.1bn25 holders, $31.8bn
Q2 202615 holders, $3.9bn26 holders, $34.6bn
RPRX

Royalty Pharma PLC

Holders
10
Reported value
$2.0bn
Buyers
7
Sellers
4

Breadth +3 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RPRX (5)

Arrowstreet Capital LP, Millennium Management LLC, PDT Partners LLC, Tudor Investment Corp, Viking Global Investors LP

Only VRTX (22)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →